PubRank

J Kienast

Author PubWeight™ 55.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995 5.24
2 Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997 3.58
3 Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000 2.70
4 Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997 2.66
5 Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000 2.48
6 Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996 1.88
7 Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003 1.86
8 Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000 1.81
9 Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med 1998 1.50
10 Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003 1.31
11 Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000 1.23
12 Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. J Am Coll Cardiol 1993 1.18
13 Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002 1.07
14 Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994 0.98
15 Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996 0.97
16 Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995 0.89
17 Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis. Leukemia 2004 0.87
18 Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2001 0.86
19 Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML. Leukemia 2011 0.85
20 Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity. Blood 1987 0.84
21 The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2008 0.83
22 Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. The ECAT Angina Pectoris Study Group. Am Heart J 1993 0.82
23 Guanine nucleotide-dependent inhibition of phospholipase C in human endothelial cells. J Biol Chem 1990 0.82
24 Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC). Bone Marrow Transplant 2001 0.81
25 Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock. Intensive Care Med 1997 0.81
26 Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. Neurol Res 1999 0.81
27 CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant 2013 0.81
28 The German competence network 'Acute and chronic leukemias'. Leukemia 2004 0.81
29 Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999 0.81
30 Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. Leukemia 2006 0.79
31 Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993 0.79
32 Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002 0.79
33 Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996 0.79
34 Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 1994 0.78
35 Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Clin Cancer Res 1999 0.78
36 Efficacy and kinetics of bone marrow processing and enrichment of haematopoietic progenitor cells (HPC) by a large-volume apheresis procedure. Bone Marrow Transplant 1997 0.78
37 Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc Res 1997 0.78
38 Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. J Infect Dis 1997 0.77
39 Minimal change glomerulonephritis with reversible proteinuria during interferon alpha 2a therapy for chronic myeloid leukemia. Am J Hematol 1995 0.77
40 Venous thromboses in particular organs. J Am Coll Cardiol 1986 0.76
41 Considerations about plasma fibrinogen concentration and the cardiovascular risk: combined evidence from the GRIPS and ECAT studies. Goettingen Risk Incidence and Prevalence Study. European Concerted Action on Thrombosis and Disabilities. Am J Cardiol 1996 0.76
42 Inflammatory mediators in BAL fluid as markers of evolving pneumonia in leukocytopenic patients. Chest 1997 0.76
43 Volume-controlled versus biphasic positive airway pressure ventilation in leukopenic patients with severe respiratory failure. Crit Care Med 1996 0.76
44 Different pathways initiating arachidonic acid (AA) release/thromboxane (TxA2) formation in human platelets--studies with fluoride and phorbol ester. Prog Clin Biol Res 1989 0.76
45 Intestinal graft-versus-host-disease staging by video capsule endoscopy. Endoscopy 2008 0.76
46 Subgroup specific therapy effects in AML: AMLCG data. Ann Hematol 2004 0.76
47 Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma 2003 0.75
48 Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Ann Hematol 2002 0.75
49 [Antithrombotic treatment following aortocoronary bypass operation]. Dtsch Med Wochenschr 1987 0.75
50 Variability over time of haemostatic and other cardiovascular risk factors in patients suffering from angina pectoris. ECAT Angina Pectoris Study Group. Thromb Haemost 1993 0.75
51 [Sepsis in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association for Hematology and Oncology]. Dtsch Med Wochenschr 1999 0.75
52 [Dyspnea, tachycardia]. Schweiz Rundsch Med Prax 1987 0.75
53 Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). Coron Artery Dis 1994 0.75
54 Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. Thromb Res 1993 0.75
55 [Experiences with goniotrepanation]. Ber Zusammenkunft Dtsch Ophthalmol Ges 1975 0.75
56 Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells. Bone Marrow Transplant 1999 0.75
57 Regulatory mechanisms in platelets. Rev Port Cardiol 1990 0.75
58 Dual effect of fluoride on endothelial prostacyclin production: a phospholipase C mediated phenomenon. Prog Clin Biol Res 1989 0.75
59 [Angiogenesis in patients with hematologic malignancies]. Onkologie 2001 0.75
60 [The value of laboratory diagnosis in thrombolytic therapy]. Internist (Berl) 1992 0.75
61 Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial. Oncology 2002 0.75
62 Pharmacology of the interaction between platelets and vessel wall. Clin Haematol 1986 0.75
63 [Epidemiology and interventional treatment strategies of infectious complications after allogenic stem-cell transplantation]. Dtsch Med Wochenschr 2001 0.75
64 Severe hepatobiliary complication in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Acta Oncol 1996 0.75
65 On the role of guanine nucleotide binding regulatory proteins (G-proteins) in signal transduction in human platelets: studies with sodium fluoride (NaF). Agents Actions Suppl 1986 0.75
66 Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin: a prospective study in acute deep venous thrombosis. Blood Coagul Fibrinolysis 1995 0.75
67 Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH). Semin Thromb Hemost 1997 0.75
68 [Platelet inhibitors or anticoagulants in prevention after myocardial infarct? The 1991 state of the art]. Z Gesamte Inn Med 1992 0.75